Galapagos NV (AMS: GLPG)
27.74
+1.74 (6.69%)
Oct 7, 2024, 5:35 PM CET
Galapagos NV Revenue
Galapagos NV had revenue of 77.87M EUR in the quarter ending June 30, 2024, with 29.67% growth. This brings the company's revenue in the last twelve months to 261.40M, up 204.24% year-over-year. In the year 2023, Galapagos NV had annual revenue of 239.72M, down -0.63%.
Revenue (ttm)
261.40M
Revenue Growth
+204.24%
P/S Ratio
6.99
Revenue / Employee
382.73K
Employees
1,123
Market Cap
1.83B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
Dec 31, 2019 | 834.90M | 517.06M | 162.68% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pharming Group N.V. | 259.04M |
ASML Holding N.V. | 25.44B |
Unilever PLC | 60.29B |
Prosus N.V. | 5.07B |
RELX PLC | 10.97B |
ING Groep N.V. | 19.58B |
Galapagos NV News
- 1 day ago - Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth - GlobeNewsWire
- 7 days ago - Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area - Business Wire
- 7 days ago - Galapagos receives transparency notification from EcoR1 Capital - GlobeNewsWire
- 21 days ago - Galapagos receives transparency notification from EcoR1 Capital - GlobeNewsWire
- 4 weeks ago - Galapagos receives transparency notification from FMR LLC - GlobeNewsWire
- 6 weeks ago - Galapagos up 10% as major shareholder intends to talk about strategy - Seeking Alpha
- 6 weeks ago - Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities' - Benzinga
- 6 weeks ago - Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats - Investor's Business Daily